原发性恶性甲状腺畸胎瘤:单中心诊治经验
回顾性分析1994—2017年MD Anderson癌症中心收治的4例病理确诊的原发性恶性甲状腺畸胎瘤,均为40岁以下年轻女性,接受手术联合或不联合化疗,中位随访172个月全部无病存活;作者结合文献建议对有广泛甲状腺外侵犯、颈部淋巴结转移和/或远处转移者采用新辅助化疗联合手术切除。
要点
- 原发性恶性甲状腺畸胎瘤极罕见,文献报道不足35例,多见于年轻女性。
- 4例均无病存活,中位随访172个月(范围52–282个月)。
- 对广泛外侵、淋巴结或远处转移者,新辅助化疗联合手术可能有益。
核心结论
- 本队列为目前文献中单中心样本量最大、随访时间最长的原发性恶性甲状腺畸胎瘤病例系列。
- 基于文献与4例经验,新辅助化疗联合手术切除对存在广泛甲状腺外侵犯、颈部淋巴结转移和/或远处转移的患者是有前景的方法。
研究设计与样本
- 回顾性病例系列,纳入1994—2017年德克萨斯大学MD Anderson癌症中心经组织病理学确诊的4例原发性恶性甲状腺畸胎瘤患者。
主要发现
- 4例均为40岁以下年轻女性。
- 1例仅行甲状腺手术,1例手术加术后辅助化疗,2例先行新辅助化疗并获得显著肿瘤退缩后再行根治性甲状腺手术。
- 无患者接受术后放疗。
- 全部患者在中位172个月(范围52–282个月)随访时仍存活且无病。
关键数值与推荐
- 所用化疗方案包括博来霉素+依托泊苷+顺铂、环磷酰胺+阿霉素+顺铂、放线菌素D+环磷酰胺+依托泊苷、博来霉素+长春新碱+顺铂、长春新碱+甲氨蝶呤+博来霉素+顺铂。
- 建议对新辅助化疗联合手术的适用条件为:广泛甲状腺外侵犯、颈部淋巴结转移和/或远处转移。
临床怎么用
- 对年轻女性原发性恶性甲状腺畸胎瘤,可考虑手术联合含铂等多药联合化疗。
- 存在广泛外侵、颈部淋巴结转移或远处转移时,可优先尝试新辅助化疗后再行根治性手术。
局限性
- 样本量仅4例,治疗 regimens 不一致,无法比较不同方案的疗效。
- 为单中心回顾性病例系列,存在选择偏倚,结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primary malignant thyroid teratomas are very rare tumors (fewer than 35 previously reported cases in the literature) typically affecting young adult women. While prognosis is poor, there have been some reports of successful treatment regimens. Four cases treated successfully are reported, and a review of the existing literature is provided. PATIENT FINDINGS: Medical records of four patients with histopathologically confirmed malignant thyroid teratomas treated at the University of Texas MD Anderson Cancer Center between 1994 and 2017 were reviewed. The patients were treated with variable treatment regimens consisting of surgical excision with or without aggressive combination chemotherapy (bleomycin, etoposide, and cisplatin; cyclophasphamide, adriamycin, and cisplatin; actinomycin-D, cyclophosphamide, and etoposide; bleomycin, vincristine, and cisplatin; or vincristine, methotrexate, bleomycin, and cisplatin). SUMMARY: All four patients were young women <40 years of age. One patient had thyroid surgery alone, another had surgery with postoperative adjuvant chemotherapy, and two patients underwent neoadjuvant chemotherapy with significant tumor regression prior to definitive thyroid surgery. No patients had postoperative radiation therapy. All patients remained alive and disease free a median of 172 months (range 52-282 months) following completion of therapy. CONCLUSIONS: This case series represents the largest and longest follow-up from a single institution in the literature to date on primary malignant thyroid teratomas. Based on the existing literature and the authors' experience with these four patients, it is suggested that neoadjuvant chemotherapy combined with surgical excision is a promising approach for patients with gross extrathyroidal extension, cervical lymph node metastases, and/or distantly metastatic disease.
引用
- Ting J, Bell D, Ahmed S, et al. Primary Malignant Thyroid Teratoma: An Institutional Experience. Thyroid. 2019. PMID: 30759052. doi:10.1089/thy.2018.0206
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。